Transaction DateRecipientSharesTypePriceValue
20th August 2020Bankole A. Johnson350,000Open or private sale$1.21$423,500.00
27th March 2020James W. Jr. Newman5,000Open or private purchase$1.42$7,100.00
27th March 2020James W. Jr. Newman10,000Open or private purchase$1.34$13,400.00
27th March 2020James W. Jr. Newman4,644Open or private purchase$1.35$6,269.40
26th March 2020William B. Iii Stilley12,652Open or private purchase$1.47$18,598.44
25th March 2020William B. Iii Stilley12,348Open or private purchase$1.13$13,953.24
3rd March 2020Joseph Truluck27,084Grant/award etc.$0.00
3rd March 2020William B. Iii Stilley54,167Grant/award etc.$0.00
12th December 2019Bankole A. Johnson150,000Open or private sale$1.00$150,000.00
2nd October 2019Bankole A. Johnson3,187Grant/award etc.$0.00
Adial Pharmaceuticals
Adial Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. Its lead product AD04, a selective serotonin-3 antagonist is in Phase 3 clinical trial.

Ticker: ADIL
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1513525
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags